Please Wait.....
Report
Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market
Market Report I 2023-10-01 I 341 Pages I Data Bridge Market Research
The global Acute Respiratory Distress Syndrome (ARDS) treatment market is expected to reach USD 9,954,720.47 thousand by 2030, from USD 4,577,440.16 thousand in 2022, growing at the CAGR of 10.6% in the forecast period of 2023 to 2030.
Market Segmentation
Global Acute Respiratory Distress Syndrome (Ards) Treatment Market, By Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause ( Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country ( U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Turkey, Hungary, Netherlands, Switzerland, Austria Lithuania, Poland, Russia, Ireland, Norway, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Israel, Egypt, Kuwait, Rest of Middle East and Africa, Brazil, Argentina, Peru, Rest of South America - Industry Trends and Forecast to 2030
Overview of Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics
Driver
- Increasing prevalence and incidence of acute lung injury in the market
Restraint
- High cost of device and treatment
Opportunity
- Strategic initiatives joined with new product launches by market players
Market Players
Some of the major market players operating in the global Acute Respiratory Distress Syndrome (ARDS) treatment market are listed below:
- Gilead Sciences, Inc.
- Terumo Medical Corporation
- Getinge
- LivaNova PLC
- Medtronic
- ResMed
- Fisher & Paykel Healthcare Limited.
- Dragerwerk AG & Co. KGaA
- NIPRO
- Fresenius SE & Co. KGaA
- Hamilton Medical
- Pfizer Inc.
- WEINMANN Emergency Medical Technology GmbH + Co. KG
- EUROSETS
- Armstrong Medical
- nice Neotech Medical Systems Pvt. Ltd.
- Besmed Health Business Corp.
TABLE OF CONTENTS
1 INTRODUCTION 41
1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.3 OVERVIEW OF GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 41
1.4 LIMITATIONS 43
1.5 MARKETS COVERED 43
2 MARKET SEGMENTATION 45
2.1 MARKETS COVERED 45
2.2 GEOGRAPHICAL SCOPE 46
2.3 YEARS CONSIDERED FOR THE STUDY 47
2.4 CURRENCY AND PRICING 47
2.5 DBMR TRIPOD DATA VALIDATION MODEL 48
2.6 MULTIVARIATE MODELLING 51
2.7 TYPE LIFELINE CURVE 51
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 52
2.9 DBMR MARKET POSITION GRID 53
2.10 MARKET END USER COVERAGE GRID 54
2.11 VENDOR SHARE ANALYSIS 55
2.12 SECONDARY SOURCES 56
2.13 ASSUMPTIONS 56
3 EXECUTIVE SUMMARY 57
4 PREMIUM INSIGHTS 60
4.1 PESTEL ANALYSIS 61
4.2 PORTER'S FIVE FORCES 62
4.3 INSURANCE REIMBURSEMENT 63
4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 63
4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 63
4.3.3 ABBOTT CODING GUIDE FOR ECMO 64
4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 64
4.3.5 CERN HEALTH INSURANCE SCHEME 65
4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 65
4.3.7 AMERICAN HOSPITAL ASSOCIATION 66
4.4 PIPELINE ANALYSIS 67
4.5 PRICING ANALYSIS 69
5 MARKET OVERVIEW 70
5.1 DRIVERS 72
5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 72
5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 72
5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 73
5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 73
5.2 RESTRAINTS 74
5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 74
5.2.2 HIGH COST OF DEVICES AND TREATMENT 74
5.3 OPPORTUNITIES 75
5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 75
5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 75
5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 76
5.4 CHALLENGES 77
5.4.1 STRINGENT RULES & REGULATIONS 77
5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 78
6 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 79
6.1 OVERVIEW 80
6.2 MECHANICAL VENTILATION 83
6.2.1 HIGH-FLOW NASAL O2 84
6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 84
6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 84
6.2.4 PRONE POSITION VENTILATION 84
6.2.5 OTHERS 85
6.3 CORTICOSTEROIDS 85
6.3.1 METHYLPREDNISOLONE 86
6.3.2 DEXAMETHASONE 86
6.3.3 OTHERS 86
6.4 ANTIVIRAL MEDICATION 87
6.4.1 RIBAVIRIN 88
6.4.2 OSELTAMIVIR 88
6.4.3 OTHERS 88
6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 88
6.6 TOCILIZUMAB 89
6.7 OTHERS 89?
7 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 90
7.1 OVERVIEW 91
7.2 SEPSIS 94
7.3 INHALATION OF HARMFUL SUBSTANCES 94
7.4 SEVERE PNEUMONIA 95
7.5 OTHERS 95
8 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 96
8.1 OVERVIEW 97
8.2 PARENTERAL 100
8.2.1 INTRAVENOUS 100
8.2.2 INTRAMUSCULAR 100
8.3 ORAL 101
8.4 OTHERS 101
9 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 102
9.1 OVERVIEW 103
9.2 HOSPITALS 106
9.3 SPECIALTY CLINICS 106
9.4 HOME HEALTHCARE 107
9.5 OTHERS 107
10 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 108
10.1 OVERVIEW 109
10.2 DIRECT TENDER 112
10.3 HOSPITAL PHARMACY 112
10.4 RETAIL PHARMACY 113
10.5 ONLINE PHARMACY 113?
11 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 114
11.1 OVERVIEW 115
11.2 NORTH AMERICA 118
11.2.1 U.S. 123
11.2.2 CANADA 128
11.2.3 MEXICO 133
11.3 EUROPE 138
11.3.1 GERMANY 143
11.3.2 FRANCE 148
11.3.3 U.K. 153
11.3.4 ITALY 158
11.3.5 SPAIN 163
11.3.6 TURKEY 168
11.3.7 NETHERLANDS 173
11.3.8 SWITZERLAND 178
11.3.9 BELGIUM 183
11.3.10 RUSSIA 188
11.3.11 REST OF EUROPE 193
11.4 ASIA-PACIFIC 194
11.4.1 JAPAN 200
11.4.2 CHINA 205
11.4.3 INDIA 210
11.4.4 SOUTH KOREA 215
11.4.5 AUSTRALIA 220
11.4.6 SINGAPORE 225
11.4.7 THAILAND 230
11.4.8 MALAYSIA 235
11.4.9 INDONESIA 240
11.4.10 PHILIPPINES 245
11.4.11 REST OF ASIA-PACIFIC 250
11.5 SOUTH AMERICA 251
11.5.1 BRAZIL 256
11.5.2 ARGENTINA 261
11.5.3 REST OF SOUTH AMERICA 266?
11.6 MIDDLE EAST AND AFRICA 267
11.6.1 SOUTH AFRICA 272
11.6.2 SAUDI ARABIA 277
11.6.3 U.A.E 282
11.6.4 ISRAEL 287
11.6.5 EGYPT 292
11.6.6 KUWAIT 297
11.6.7 REST OF MIDDLE EAST AND AFRICA 302
12 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 303
12.1 COMPANY SHARE ANALYSIS: GLOBAL 303
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 304
12.3 COMPANY SHARE ANALYSIS: EUROPE 305
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 306
13 SWOT ANALYSIS 307
14 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 308
14.1 GILEAD SCIENCES INC. 308
14.1.1 COMPANY SNAPSHOT 308
14.1.2 REVENUE ANALYSIS 309
14.1.3 COMPANY SHARE ANALYSIS 309
14.1.4 PRODUCT PORTFOLIO 310
14.1.5 RECENT DEVELOPMENT 310
14.2 TERUMO CORPORATION 311
14.2.1 COMPANY SNAPSHOT 311
14.2.2 REVENUE ANALYSIS 311
14.2.3 COMPANY SHARE ANALYSIS 312
14.2.4 PRODUCT PORTFOLIO 312
14.2.5 RECENT DEVELOPMENT 312
14.3 GETINGE 313
14.3.1 COMPANY SNAPSHOT 313
14.3.2 REVENUE ANALYSIS 313
14.3.3 COMPANY SHARE ANALYSIS 314
14.3.4 PRODUCT PORTFOLIO 314
14.3.5 RECENT DEVELOPMENT 314?
14.4 LIVANOVA PLC 315
14.4.1 COMPANY SNAPSHOT 315
14.4.2 REVENUE ANALYSIS 315
14.4.3 COMPANY SHARE ANALYSIS 316
14.4.4 PRODUCT PORTFOLIO 316
14.4.5 RECENT DEVELOPMENTS 316
14.5 MEDTRONIC 317
14.5.1 COMPANY SNAPSHOT 317
14.5.2 REVENUE ANALYSIS 317
14.5.3 COMPANY SHARE ANALYSIS 318
14.5.4 PRODUCT PORTFOLIO 318
14.5.5 RECENT DEVELOPMENTS 318
14.6 ARMSTRONG MEDICAL 319
14.6.1 COMPANY SNAPSHOT 319
14.6.2 PRODUCT PORTFOLIO 319
14.6.3 RECENT DEVELOPMENT 319
14.7 BESMED HEALTH BUSINESS CORP. 320
14.7.1 COMPANY SNAPSHOT 320
14.7.2 PRODUCT PORTFOLIO 320
14.7.3 RECENT DEVELOPMENTS 321
14.8 DRAGERWERK AG & CO. KGAA 322
14.8.1 COMPANY SNAPSHOT 322
14.8.2 REVENUE ANALYSIS 322
14.8.3 PRODUCT PORTFOLIO 323
14.8.4 RECENT DEVELOPMENTS 323
14.9 EUROSETS 324
14.9.1 COMPANY SNAPSHOT 324
14.9.2 PRODUCT PORTFOLIO 324
14.9.3 RECENT DEVELOPMENT 324
14.10 FISHER & PAYKEL HEALTHCARE LIMITED 325
14.10.1 COMPANY SNAPSHOT 325
14.10.2 REVENUE ANALYSIS 325
14.10.3 PRODUCT PORTFOLIO 326
14.10.4 RECENT DEVELOPMENTS 326
14.11 FRESENIUS SE & CO. KGAA. 327
14.11.1 COMPANY SNAPSHOT 327
14.11.2 REVENUE ANALYSIS 327
14.11.3 PRODUCT PORTFOLIO 328
14.11.4 RECENT DEVELOPMENT 328?
14.12 HAMILTON MEDICAL 329
14.12.1 COMPANY SNAPSHOT 329
14.12.2 PRODUCT PORTFOLIO 329
14.12.3 RECENT DEVELOPMENT 329
14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD. 330
14.13.1 COMPANY SNAPSHOT 330
14.13.2 PRODUCT PORTFOLIO 330
14.13.3 RECENT DEVELOPMENT 330
14.14 NIPRO 331
14.14.1 COMPANY SNAPSHOT 331
14.14.2 REVENUE ANALYSIS 331
14.14.3 PRODUCT PORTFOLIO 332
14.14.4 RECENT DEVELOPMENT 332
14.15 PFIZER INC. 333
14.15.1 COMPANY SNAPSHOT 333
14.15.2 REVENUE ANALYSIS 333
14.15.3 PRODUCT PORTFOLIO 334
14.15.4 RECENT DEVELOPMENT 334
14.16 RESMED 335
14.16.1 COMPANY SNAPSHOT 335
14.16.2 REVENUE ANALYSIS 335
14.16.3 PRODUCT PORTFOLIO 336
14.16.4 RECENT DEVELOPMENT 336
14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 337
14.17.1 COMPANY SNAPSHOT 337
14.17.2 PRODUCT PORTFOLIO 337
14.17.3 RECENT DEVELOPMENT 337
15 QUESTIONNAIRE 338
16 RELATED REPORTS 341
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security